Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2000

View Archived Issues

Study results for Targretin in NSCLC support phase III program

Immtech awards grant to study potential leishmaniasis treatments

B-cells carrying HIV may pass the virus to T-cells

LU-135252 improves hemodynamics in clinical CHF

Bristol-Myers Squibb's VPI BMS-189921 inhibits NEP and ACE in vivo

C. difficile toxin binding polymer demonstrates tolerability in phase I trial

New indication for KW-6002 undergoes clinical testing

Forest signs agreement with NPS Allelix for migraine therapy

Beneficial effects of PAF antagonist in patients with bronchial asthma

ERS highlights: orazipone prevents eosinophilia in animal models of lung inflammation

Potent in vitro anti-HIV activity reported for new CCR5 antagonists at ACS

Micro Therapeutics to expand Onyx LES trial in brain aneurysm

Arimidex approved by FDA as first-line therapy of breast cancer

Cytogen and Northwest Biotherapeutics execute PSMA sublicense agreement

Early and late cardioprotective efficacy described for new prostanoid

Ischemically induced ventricular fibrillation safely prevented by HMR-1402

Health Canada requests additional clinical data for Pennsaid NDS

Antiinflammatory compounds with macrolide structure designed by Zambon

Patent covers SB's new antiallergic agents acting on chemokine receptors

Selective D3 receptor modulators and their use reported in BASF patent

New PDE4 inhibitors from Byk Gulden useful for respiratory disorders

Orally available carbapenems synthesized and evaluated by Sankyo researchers

New agents for glaucoma reported by Santen

Aventis presents new hypoglycemic agents

Preparation and use of novel nAChR ligands disclosed in recent patent

SuperGen updates progress of phase III rubitecan trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...